The MEDNAX Inc (MD) Price Target Cut to $58.00 by Analysts at Mizuho

The MEDNAX Inc (MD) Price Target Cut to $58.00 by Analysts at Mizuho

Other equities analysts have also recently issued reports about the stock. Jefferies Group LLC reissued a hold rating and issued a $58.00 price objective on shares of MEDNAX in a research note on Wednesday, April 26th. TheStreet cut shares of MEDNAX from a b- rating to a c+ rating in a research note on Tuesday, May 16th. Stifel Nicolaus dropped their price objective on shares of MEDNAX from $65.00 to $58.00 and set a hold rating on the stock in a research note on Thursday, May 25th. Zacks Investment Research raised shares of MEDNAX from a sell rating to a hold rating in a research note on Wednesday, April 19th. Finally, JPMorgan Chase & Co. reissued a neutral rating and issued a $69.00 price objective on shares of MEDNAX in a research note on Friday, March 10th. One equities research analyst has rated the stock with a sell rating and ten have assigned a hold rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $66.25.

MEDNAX Inc (NYSE:MD) had its target price lowered by Mizuho from $64.00 to $58.00 in a report issued on Tuesday. The brokerage currently has a neutral rating on the stock.

In related news, Director Manuel Kadre purchased 21,704 shares of the stock in a transaction dated Friday, May 5th. The shares were acquired at an average cost of $55.79 per share, with a total value of $1,210,866.16. Following the purchase, the director now directly owns 111,255 shares in the company, valued at approximately $6,206,916.45. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph M. Calabro sold 23,327 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the transaction, the insider now directly owns 296,379 shares in the company, valued at $16,300,845. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock. Institutional investors have recently bought and sold shares of the company. Achmea Investment Management B.V. bought a new position in MEDNAX during the first quarter worth $966,000. Grandeur Peak Global Advisors LLC boosted its position in MEDNAX by 2.3% in the first quarter. Grandeur Peak Global Advisors LLC now owns 187,825 shares of the company’s stock worth $13,031,000 after buying an additional 4,200 shares during the period. HighTower Advisors LLC boosted its position in MEDNAX by 63.4% in the first quarter. HighTower Advisors LLC now owns 35,582 shares of the company’s stock worth $2,461,000 after buying an additional 13,810 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in MEDNAX by 0.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 89,929 shares of the company’s stock worth $6,239,000 after buying an additional 832 shares during the period. Finally, Jane Street Group LLC bought a new position in MEDNAX during the first quarter worth $419,000. 99.16% of the stock is currently owned by institutional investors and hedge funds.

MEDNAX Company Profile MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “MD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for MEDNAX Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MEDNAX Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment